Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Carbamazepine on Erdafitinib PK
NCT04330248Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib in urothelial carcinoma (UC), sponsored by Johnson & Johnson. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Analyte Concentration-Time Curve from Time 0 to 168 hours and 2 more. Started Mar 2020; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04330248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330248.